Jaguar Health, Inc.: management transactions · United States · SEC (Form 4)

About Jaguar Health, Inc.

Jaguar Health, Inc. (NASDAQ: JAGX) is a United States-based specialty pharmaceutical company listed on the NASDAQ market and headquartered in San Francisco, California, United States. The company was founded on June 6, 2013, originally as Jaguar Animal Health, Inc., with a mission to develop and commercialize prescription and non-prescription products for companion animals and livestock. After its merger with Napo Pharmaceuticals in 2017, the business was renamed Jaguar Health, Inc. and gradually shifted its strategic focus toward human health, while retaining an animal-health legacy in its broader corporate history. Today, Jaguar Health is best described as a commercial-stage and development-stage pharmaceutical company focused on gastrointestinal disorders. Its lead asset is crofelemer, a plant-derived compound extracted from the red latex sap of Croton lechleri, an Amazonian tree. Crofelemer underpins the company’s human-health strategy and is central to its rare-disease intestinal failure pipeline. Jaguar also markets or has marketed prescription products including Mytesi, Gelclair and Canalevia-CA1, alongside non-prescription animal-health products such as Neonorm. This portfolio gives the company a differentiated profile in biopharma, combining natural-product sourcing, GI-focused therapeutics and both human and animal health applications. From a competitive standpoint, Jaguar Health occupies a small-cap niche position with a relatively concentrated revenue base and a heavy reliance on a limited number of products and clinical programs. That creates meaningful upside optionality if regulatory, clinical or partnership milestones are achieved, but it also leaves the company exposed to the execution and financing risks common to micro-cap biotechnology and specialty pharma names. The company emphasizes sustainable sourcing and fair-trade practices for crofelemer supply, which supports its brand positioning in plant-based medicine. Geographically, Jaguar’s operating base is primarily the United States, with its principal executive offices in San Francisco and its equity trading on NASDAQ under JAGX. Recent developments have been notable. In January 2026, Jaguar signed a U.S. license agreement with Future Pak covering Mytesi and Canalevia-CA1, providing non-dilutive capital and allowing management to concentrate resources on late-stage crofelemer development for rare intestinal failure indications. In March 2026, the company announced a balance-sheet restructuring that reduced royalty and debt obligations. Jaguar also faced Nasdaq compliance issues during 2026, underscoring the company’s still-fragile market profile and the importance of ongoing capital, clinical and listing-rule execution.